The Pediatric Research Equity Act aims to close the gap in pediatric drug testing but faces significant delays in study completion. Rare disease designations exempt nearly half of new drugs from ...
Drugs issued rare pediatric disease priority review vouchers that were redeemed had revenues that were similar to other brand drugs, according to recent research published in The Journal of Pediatrics ...
Please provide your email address to receive an email when new articles are posted on . No drugs approved between 2017 and 2020 were subjected to post-approval pediatric testing requirements. After ...
Global Pediatric Development of Drugs, Biologics, and Medical Devices takes an in-depth look at creating and implementing a global regulatory strategy for bringing pediatric drug products and ...
On May 17, the U.S. Food & Drug Administration (“FDA”) issued two important draft guidance documents, which clarify the agency’s approach to requirements and incentives in the realm of pediatric drug ...
Introduction Pediatric Pharmacology Disasters Testing Drugs in Children Legal and Regulatory Developments: Pediatric Pharmacology in the United States References Legal and Regulatory Developments: ...
On February 3, 2026, the President signed the Consolidated Appropriations Act of 2026 (the CAA) into law and ended a partial government shutdown. 1 The Act included two changes that directly affect ...
Only an estimated 5 percent of rare pediatric diseases have a treatment, although collectively they affect more than ten million children in the US. To stimulate drug development for rare pediatric ...
NEW ORLEANS ― Even within the first year of implementation, the Research to Accelerate Cures and Equity (RACE) for Children Act has made an impact. "In the year prior to RACE implementation, there ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results